丁硫胺氧化物（BSO）是一种合成的氨基酸，可以阻断还原型谷胱甘肽（GSH）的生物合成，GSH 是肿瘤细胞中存在的内源性抗氧化细胞成分。GSH 水平与肿瘤细胞对化疗药物和铂类化合物的抗药性相关。因此，通过耗尽 GSH，BSO 可增强耐药性肿瘤中化疗药物的细胞毒性。因此，本研究旨在对使用 BSO 的癌症治疗进行系统评价与荟萃分析预临床研究。系统搜索使用以下数据库进行，包括 PubMed、Web of Science、Scopus 和 EMBASE，截至2023年3月20日，以收集评估 BSO 作为抗肿瘤治疗策略的预临床研究。找到109项研究，评估了 BSO 单独或与其他化合物联用的细胞毒性潜能。其中21项满足进行荟萃分析的条件。收集到的证据表明，BSO 单独展示了细胞毒性活性。然而，通常将该化合物与其他抗肿瘤策略，主要是化疗策略一起使用，以提高对致癌细胞的细胞毒性和治疗效果。最后，本综述对于 BSO 在癌症治疗中的应用提供了重要的考虑，这可能会优化未来作为辅助抗肿瘤治疗工具的研究。

Buthionine sulfoximine (BSO) is a synthetic amino acid that blocks the biosynthesis of reduced glutathione (GSH), an endogenous antioxidant cellular component present in tumor cells. GSH levels have been associated with tumor cell resistance to chemotherapeutic drugs and platinum compounds. Consequently, by depleting GSH, BSO enhances the cytotoxicity of chemotherapeutic agents in drug-resistant tumors. Therefore, the aim of this study was to conduct a systematic review with meta-analysis of preclinical studies utilizing BSO in cancer treatments. The systematic search was carried out using the following databases: PubMed, Web of Science, Scopus, and EMBASE up until March 20, 2023, in order to collect preclinical studies that evaluated BSO, alone or in association, as a strategy for antineoplastic therapy. One hundred nine investigations were found to assess the cytotoxic potential of BSO alone or in combination with other compounds. Twenty-one of these met the criteria for performing the meta-analysis. The evidence gathered indicated that BSO alone exhibits cytotoxic activity. However, this compound is generally used in combination with other antineoplastic strategies, mainly chemotherapy ones, to improve cytotoxicity to carcinogenic cells and treatment efficacy. Finally, this review provides important considerations regarding BSO use in cancer treatment conditions, which might optimize future studies as a potential adjuvant antineoplastic therapeutic tool.